Clinical Trials Logo

Stage III Penile Cancer AJCC v8 clinical trials

View clinical trials related to Stage III Penile Cancer AJCC v8.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06104618 Recruiting - Clinical trials for Stage IV Penile Cancer AJCC v8

Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

Start date: December 21, 2023
Phase: Phase 2
Study type: Interventional

This phase II trial tests how well enfortumab vedotin works for treating patients with squamous cell carcinoma of the penis that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of tumor cells. Enfortumab attaches to a protein called nectin-4 on tumor cells in a targeted way and delivers vedotin to kill them.